Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Wang, Yucai, Link, Brian K., Witzig, Thomas E., Maurer, Matthew J., Allmer, Cristine, King, Rebecca L., Feldman, Andrew L., Habermann, Thomas M., Ansell, Stephen M., Slager, Susan L., Cerhan, James R., Nowakowski, Grzegorz S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888139/
https://ncbi.nlm.nih.gov/pubmed/31350266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000858
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars